In our previous reports, we showed that both FGF21 and FGF19 have profound beneficial effects in normalizing local and systemic metabolic parameters through targeting adipose tissues and liver, and are excellent candidates or pathway targets for treatment of obesity, diabetes and metabolic disorders [13,17,18,20]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.